279 related articles for article (PubMed ID: 9932169)
1. Hemolytic-uremic syndrome caused by gemcitabine.
Nackaerts K; Daenen M; Vansteenkiste J; Vandevelde A; Van Bleyenbergh P; Demedts M
Ann Oncol; 1998 Dec; 9(12):1355. PubMed ID: 9932169
[No Abstract] [Full Text] [Related]
2. Gemcitabine-induced hemolytic uremic syndrome: a case report.
Brodowicz T; Breiteneder S; Wiltschke C; Zielinski CC
J Natl Cancer Inst; 1997 Dec; 89(24):1895-6. PubMed ID: 9414181
[No Abstract] [Full Text] [Related]
3. Gemcitabine and haemolytic-uraemic syndrome.
Ruiz I; Del Valle J; Gómez A
Ann Oncol; 2004 Oct; 15(10):1575-6. PubMed ID: 15367421
[No Abstract] [Full Text] [Related]
4. Hemolytic uremic syndrome due to gemcitabine in a young woman with cholangiocarcinoma.
Nieto-Ríos JF; Zuluaga-Quintero M; Higuita LM; Rincón CI; Galvez-Cárdenas KM; Ocampo-Kohn C; Aristizabal-Alzate A; Florez-Vargas AA; Zuluaga-Valencia GA
J Bras Nefrol; 2016 Jun; 38(2):255-9. PubMed ID: 27438981
[TBL] [Abstract][Full Text] [Related]
5. Hemolytic-uremic syndrome associated with gemcitabine: a case report and review of literature.
Saif MW; McGee PJ
JOP; 2005 Jul; 6(4):369-74. PubMed ID: 16006690
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine hydrochloride: combination of activity and tolerability. Proceedings of a symposium. Jerusalem, Israel, November 14, 1993.
Anticancer Drugs; 1995 Dec; 6 Suppl 6():5-65. PubMed ID: 8718418
[No Abstract] [Full Text] [Related]
7. Veno-occlusive disease of the liver induced by gemcitabine.
Dobbie M; Hofer S; Oberholzer M; Herrmann R
Ann Oncol; 1998 Jun; 9(6):681. PubMed ID: 9681086
[No Abstract] [Full Text] [Related]
8. [Hemolytic-uremic syndrome associated with gemcitabine use: report of one case].
Vega J; Parodi C; Méndez GP; Goecke H
Rev Med Chil; 2013 Jun; 141(6):797-802. PubMed ID: 24121585
[TBL] [Abstract][Full Text] [Related]
9. Severe hemolytic uremic syndrome in an advanced ovarian cancer patient treated with carboplatin and gemcitabine.
Gross M; Hiesse C; Kriaa F; Goldwasser F
Anticancer Drugs; 1999 Jul; 10(6):533-6. PubMed ID: 10885900
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine and low dose carboplatin in the treatment of elderly patients with advanced non-small cell lung cancer.
Maestu I; Gómez-Aldaraví L; Torregrosa MD; Camps C; Llorca C; Bosch C; Gómez J; Giner V; Oltra A; Albert A
Lung Cancer; 2003 Dec; 42(3):345-54. PubMed ID: 14644523
[TBL] [Abstract][Full Text] [Related]
11. [Hemolytic uremic syndrome as a complication of gemcitabine treatment: report of six cases and review of the literature].
Desramé J; Duvic C; Bredin C; Béchade D; Artru P; Brézault C; Defuentes G; Poirier JM; Dourthe LM; Coutant G; Chaussade S; de Gramont A; Algayres JP
Rev Med Interne; 2005 Mar; 26(3):179-88. PubMed ID: 15777580
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine-induced hemolytic uremic syndrome in pancreatic cancer: a case report and review of the literature.
Lee HW; Chung MJ; Kang H; Choi H; Choi YJ; Lee KJ; Lee SW; Han SH; Kim JS; Song SY
Gut Liver; 2014 Jan; 8(1):109-12. PubMed ID: 24516709
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine--a major advance?
Thomas A; Steward WP
Ann Oncol; 1998 Dec; 9(12):1265-7. PubMed ID: 9932153
[No Abstract] [Full Text] [Related]
14. Randomized, multicenter, phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer.
Mazzanti P; Massacesi C; Rocchi MB; Mattioli R; Lippe P; Trivisonne R; Buzzi F; De Signoribus G; Tuveri G; Rossi G; Di Lullo L; Sturba F; Morale D; Catanzani S; Pilone A; Bonsignori M; Battelli T
Lung Cancer; 2003 Jul; 41(1):81-9. PubMed ID: 12826316
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of gemcitabine and vindesine in patients with previously untreated non-resectable non-small-cell lung cancer.
Sørensen JB; Bergman B; Nielsen AL; Krarup M; Dombernowsky P; Hansen HH
Br J Cancer; 1999 Feb; 79(5-6):875-81. PubMed ID: 10070884
[TBL] [Abstract][Full Text] [Related]
16. [A case of hemolytic uremic syndrome after adjuvant chemotherapy with gemcitabine in a patient with pancreatic cancer].
Wato M; Inaba T; Ishikawa H; Ishikawa S; Baba N; Miyoshi M; Senoh T; Nagano T; Takaguchi K; Watanabe S; Kawai K
Nihon Shokakibyo Gakkai Zasshi; 2010 Oct; 107(10):1676-85. PubMed ID: 20938119
[TBL] [Abstract][Full Text] [Related]
17. [Hemolytic uremic syndrome induced by gemcitabine. A poorly recognized complication?].
Graas MP; Houbiers G; Demolin G; Stultiens A; Focan C
Rev Med Liege; 2012 Dec; 67(12):644-8. PubMed ID: 23342875
[TBL] [Abstract][Full Text] [Related]
18. Haemolytic uraemic syndrome after gemcitabine treatment for pancreatic carcinoma.
Choi M; Woywodt A; Göbel U; Schneider W; Kettritz R
Nephrol Dial Transplant; 1999 Oct; 14(10):2523-4. PubMed ID: 10528696
[No Abstract] [Full Text] [Related]
19. Livedo racemosa and hemolytic uremic syndrome induced by gemcitabine.
Tognetti L; Garosi G; Rongioletti F; Fimiani M; Rubegni P
Int J Dermatol; 2016 Oct; 55(10):e555-6. PubMed ID: 27125732
[No Abstract] [Full Text] [Related]
20. [Is the frequency of hemolytic uremic syndrome as a complication of gemcitabine underestimated? The role of systematic screening].
Desramé J; Duvic C; Béchade D; Bredin C; Raynaud JJ; Defuentes G; Dourthe LM; Algayres JP
Gastroenterol Clin Biol; 2006 Feb; 30(2):332-4. PubMed ID: 16565677
[No Abstract] [Full Text] [Related]
[Next] [New Search]
